

HE Minister Saira Afzal Tarar
Ministry of National Health Services, Regulations and Coordination
Government of Pakistan

16 December 2016

2017 Renewal of Gavi vaccine support and New Support for the Rotavirus Vaccine

Honorable Minister,


I am writing with regard to Pakistan's request for the renewal of Gavi support to the Inactivated Polio Vaccine, Pneumococcal and Pentavalent vaccines which were reviewed by Gavi High Level Review Panel on 5 to 7 of October 2016. Further, we are pleased to confirm new support from Gavi for the Rotavirus vaccine.

The attached Appendices include the following important information:

Appendix A: Financial and Programatic information – Support for Inactivated Polio Vaccine (IPV)
Appendix B: Financial and Programatic information – Support for Pneumococcal Vaccine (PCV)
Appendix C: Financial and Programatic information – Support for Pentavalent Vaccine
Appendix D: Financial and Programatic information – Support for Rotavirus Vaccine
Appendix E: Financial and Programatic information – Support for Injection Safety Devices

Please do not hesitate to contact my colleague Dr. Hamidreza Setayesh (hsetayesh@gavi.org) if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

Appendix A: Pakistan Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Pakistan			
2. Grant number: 1518-PAK-25c-X			
3. Date of Decision Letter: 16 December 2016			
4. Date of the Partnership Framework Agreement: 19 May 2015			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID			
8. Programme duration ² : 2015 - 2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2016	2017	Total
Programme Budget (US\$)	6,402,713	5,086,000	11,488,713
10. Vaccine introduction grant: US\$ 3,420,894 disbursed in 2015 to WHO and UNICEF			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)			
Type of supplies to be purchased with Gavi funds in each year	2017		
Number of IPV vaccines doses	5,674,900		
Annual Amounts (US\$)	5,086,000		
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Not applicable			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

Gavi's usual co-financing requirements do not apply to IPV. However, Pakistan is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2016

Appendix B: Pakistan Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Pakistan				
2. Grant number: 1718-PAK-12b-X				
3. Date of Decision Letter: 16 December 2016				
4. Date of the Partnership Framework Agreement: 19 May 2016				
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID				
8. Programme duration¹: 2012 - 2018				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2012-2016	2017	2018	Total ²
Programme Budget (US\$)	US\$330,679,398 ³	US\$46,899,000	US\$47,834,500	US\$425,412,898
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)				
Type of supplies to be purchased with Gavi funds in each year	2012-2016	2017		
Number of Pneumococcal vaccines doses		13,331,600		
Annual Amounts (US\$)	US\$330,679,398 ⁴	US\$46,899,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1718-PAK-12b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition. According to the co-financing policy, the Country falls within the group Preparatory transition. Following the approved Country Tailored Approach for Pakistan that allows the alignment of timing of country's co-financing requirements with its fiscal year. Pakistan is required to fulfil the following obligations covering fiscal year 2017/2018 by the 30th June 2018.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	FY 2017/2018
Number of vaccine doses	7,587,400
Number of AD syringes	7,644,600
Number of re-constitution syringes	
Number of safety boxes	84,100
Value of vaccine doses (US\$)	US\$23,141,413
Total co-financing payments (US\$) (including freight)	US\$23,743,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2016

Appendix C: Pakistan Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Pakistan				
2. Grant number: 1718-PAK-04a-X				
3. Date of Decision Letter: 16 December 2016				
4. Date of the Partnership Framework Agreement: 19 May 2016				
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID				
8. Programme duration⁵: 2008 - 2018				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2008-2016	2017	2018	To
Programme Budget (US\$)	326,225,414 ⁷	26,650,500	24,558,000	377,433,9
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁸				
Type of supplies to be purchased with Gavi funds in each year	2008-2016	2017		
Number of Pentavalent vaccines doses		14,451,500		
Annual Amounts (US\$)	326,225,414 ⁹	\$26,650,500		
12. Procurement agency: UNICEF shall be the procurement agency for vaccines purchased with Gavi funding.				
13. Self-procurement: Self-procurement applies to co-financed portion. Please refer to the partnership framework agreement terms and conditions.				

⁵ This is the entire duration of the Programme.

⁶ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁷ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁸ This is the amount that Gavi has approved.

⁹ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1718-PAK-04a-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition. Following the approved Country Tailored Approach for Pakistan that allows the alignment of timing of country's co-financing requirements with its fiscal year. Pakistan is required to fulfil the following obligations covering fiscal year 2017/2018 by the 30th June 2018.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	FY 2017/2018
Number of vaccine doses	3,005,600
Number of AD syringes	3,154,800
Number of safety boxes	34,725
Value of vaccine doses (US\$)	5,334,867
Total co-financing payments (US\$) (including freight)	5,702,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2016

Appendix D: Pakistan Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Pakistan			
2. Grant number: 1718-PAK-13b-X / 17-PAK-08b-Y			
3. Date of Decision Letter: 16 December 2016			
4. Date of the Partnership Framework Agreement: 19 May 2015			
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme duration¹: 2017 - 2018			
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2017	2018	Total ²
Programme Budget (US\$)	US\$22,856,500	US\$19,866,500	US\$42,723,000
10. Vaccine introduction grant (in US\$): 5,445,153. Payable up to six months before vaccine introduction.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³			
Type of supplies to be purchased with Gavi funds in each year			2017
Number of Rotavirus vaccines doses			10,164,000
Number of AD syringes			
Number of re-constitution syringes			
Number of safety boxes			
Annual Amounts (US\$)			US\$22,856,500
12. Procurement agency: UNICEF shall procure vaccines using Gavi funds			
13. Self-procurement: Self-procurement applies to co-financed portion.			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

14. Co-financing obligations: Reference code: 1718-PAK-13b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year(s). Following the approved Country Tailored Approach for Pakistan that allows the alignment of timing of country's co-financing requirements with its fiscal year, Pakistan is required to fulfill obligations covering fiscal 2017/2018 by 30th of June 2018.

Type of supplies to be purchased with Country funds in each year	FY 2017/2018
Number of vaccine doses	3,172,500
Value of vaccine doses (US\$)	US\$6,945,333
Total co-financing payments (US\$) (including freight)	US\$7,130,500

15. Operational support for campaigns: Not applicable

	2017	2018
Grant amount (US\$)	US\$	US\$

16. Additional reporting requirements:


Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 16 December 2016

Appendix E: Pakistan Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Pakistan			
2. Grant number: 17-PAK-32a-X; 18-PAK-32a-X			
3. Date of Decision Letter: 16 December 2016			
4. Date of the Partnership Framework Agreement: 19 May 2015			
5. Programme title: Injection Safety Devices ¹			
6. Programme duration²: 2017 - 2018			
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2017	2018	Total ³
Programme Budget (US\$)	1,702,500	1,397,500	3,100,000
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)			
TOTAL injection safety devices to be purchased with Gavi funds in each year		2017	
Number of AD syringes		33,757,000	
Number of safety boxes		371,375	
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)		1,702,500	
Injection safety devices to be purchased with Gavi funds in each year, by type of support			
New Vaccine Support (NVS), Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID, Routine		2017	
Number of AD syringes		13,432,200	
Number of safety boxes		147,775	
Annual Amounts for injection safety devices for Vaccine (US\$)		677,500	

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	2017
Number of AD syringes	15,169,000
Number of safety boxes	166,875
Annual Amounts for injection safety devices for Vaccine (US\$)	765,000
New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID, Routine	2017
Number of AD syringes	5,155,800
Number of safety boxes	56,725
Annual Amounts for injection safety devices for Vaccine (US\$)	260,000
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. UNICEF shall procure vaccines using Gavi funds	
10. Self-procurement: Self-procurement applies to co-financed portion. Please refer to the partnership framework agreement terms and conditions.	
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2016